MiMedx Group Inc (MDXG) Shares are Down -3.92%

MiMedx Group Inc (MDXG) has risen sharply, recording gains of 16.89% in the past 4 weeks. However, the stock has corrected -3.92% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 17.53% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 0.68% and the 50-Day Moving Average is 8.86%.The 200 Day SMA reached 6.31%

MiMedx

MiMedx Group Inc (NASDAQ:MDXG): After opening at $8.42, the stock dipped to an intraday low of $8.205 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $8.58 and the buying power remained strong till the end. The stock closed at $8.58 for the day, a gain of 2.75% for the day session. The total traded volume was 719,705. The stocks close on the previous trading day was $8.58.

MiMedx Group Inc (MDXG) : Currently there are 5 street experts covering MiMedx Group Inc (MDXG) stock. The most bullish and bearish price target for the stock is $13 and $9 respectively for the short term. The average price target of all the analysts comes to $11.6. The estimated standard deviation from the target is $1.52.

MiMedx Group, Inc. (MiMedx) is an integrated developer, manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Companys biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program, mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant, which is referred as an allograft. MiMedx is the supplier of amniotic tissue, having supplied over 350,000 allografts for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.